NASDAQ : CTMX
CytomX Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 2.34 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 509.88M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
CytomX Therapeutics, Inc. (CTMX) reported revenue of 18.30M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | 18.30M | 76.20M | 138.10M | 101.21M | 53.16M | 37.31M |
| Gross Profit | 18.30M | 76.20M | 138.10M | 101.21M | 53.16M | 37.31M |
| Selling, General & Admin | 32.08M | 28.74M | 29.73M | 30.02M | 40.45M | 39.16M |
| Research & Development | 73.38M | 67.03M | 83.38M | 77.68M | 106.55M | 114.19M |
| Operating Expenses | 105.46M | 95.77M | 113.11M | 107.70M | 147.00M | 153.35M |
| Operating Income | -87.15M | -19.56M | 25.00M | -6.48M | -93.83M | -116.04M |
| Interest & Investment Income | 7.72M | 5.21M | 7.14M | 9.84M | 1.68M | 255.00K |
| Currency Exchange Gain (Loss) | 11.00K | 28.00K | -38.00K | -30.00K | 340.00K | -83.00K |
| EBT Excluding Unusual Items | -79.42M | -14.33M | 32.09M | 3.32M | -91.82M | -115.87M |
| Merger & Restructuring Charges | -2.80M | -7.50M | ||||
| Pretax Income | -79.42M | -17.13M | 32.09M | 3.32M | -99.32M | -115.87M |
| Income Tax Expense | 231.00K | 238.00K | 224.00K | 3.89M | ||
| Net Income | -79.65M | -17.37M | 31.87M | -569.00K | -99.32M | -115.87M |
| Preferred Dividends & Other Adjustments | 3.00M | 3.00M | ||||
| Net Income to Common | -82.66M | -20.37M | 31.87M | -569.00K | -99.32M | -115.87M |
| Shares Outstanding (Basic) | 182.94M | 137.94M | 84.44M | 73.81M | 65.74M | 64.15M |
| Shares Outstanding (Diluted) | 182.94M | 137.94M | 84.75M | 73.81M | 65.74M | 64.15M |
| EPS (Basic) | -0.45 | -0.15 | 0.38 | -0.01 | -1.51 | -1.81 |
| EPS (Diluted) | -0.45 | -0.15 | 0.38 | -0.01 | -1.51 | -1.81 |
| Free Cash Flow | -82.48M | -75.81M | -86.54M | -56.88M | -112.53M | -120.64M |
| Free Cash Flow Per Share | -0.45 | -0.55 | -1.02 | -0.77 | -1.71 | -1.88 |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Margin | -476.17% | -25.67% | 18.10% | -6.41% | -176.50% | -311.00% |
| Profit Margin | -451.59% | -26.73% | 23.08% | -0.56% | -186.82% | -310.54% |
| Free Cash Flow Margin | -450.65% | -99.48% | -62.66% | -56.19% | -211.67% | -323.33% |
| EBITDA | -86.21M | -18.19M | 26.76M | -4.31M | -91.39M | -113.34M |
| EBITDA Margin | -23.87% | 19.38% | -4.26% | -171.91% | ||
| D&A For EBITDA | 942.00K | 1.38M | 1.77M | 2.17M | 2.44M | 2.71M |
| EBIT | -87.15M | -19.56M | 25.00M | -6.48M | -93.83M | -116.04M |
| EBIT Margin | -25.67% | 18.10% | -6.41% | -176.50% | ||
| Effective Tax Rate | 0.70% | 117.12% |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 17.22M | 12.67M | 38.05M | 17.17M | 193.65M | 205.53M |
| Short-Term Investments | 313.06M | 124.39M | 62.57M | 157.34M | 99.70M | |
| Cash & Short-Term Investments | 330.28M | 137.05M | 100.62M | 174.51M | 193.65M | 305.23M |
| Receivables | 38.99M | 2.01M | 3.10M | 3.43M | 35.99M | 790.00K |
| Prepaid Expenses | 2.96M | 4.86M | 3.58M | 5.00M | 7.47M | 4.29M |
| Total Current Assets | 373.15M | 143.92M | 107.31M | 182.94M | 237.10M | 310.30M |
| Property, Plant & Equipment | 6.12M | 4.70M | 10.60M | 16.18M | 21.02M | 25.32M |
| Goodwill | 949.00K | 949.00K | 949.00K | 949.00K | 949.00K | 949.00K |
| Other Intangible Assets | 365.00K | 438.00K | 583.00K | 729.00K | 875.00K | 1.02M |
| Other Long-Term Assets | 641.00K | 1.56M | 1.09M | 1.00M | 944.00K | 1.82M |
| Total Assets | 381.23M | 151.57M | 120.53M | 201.79M | 260.89M | 339.41M |
| Accounts Payable | 1.94M | 1.30M | 1.09M | 1.46M | 2.81M | 2.82M |
| Accrued Expenses | 12.35M | 14.17M | 12.34M | 17.60M | 22.82M | 30.62M |
| Current Portion of Leases | 1.50M | 4.24M | 5.14M | 4.59M | 4.08M | 3.62M |
| Current Unearned Revenue | 24.07M | 26.88M | 67.20M | 132.27M | 121.27M | 40.82M |
| Other Current Liabilities | 23.00K | 1.63M | ||||
| Total Current Liabilities | 39.86M | 46.62M | 85.77M | 155.91M | 152.61M | 77.87M |
| Long-Term Leases | 4.21M | 4.24M | 9.38M | 13.97M | 18.06M | |
| Long-Term Unearned Revenue | 30.62M | 1.59M | 26.86M | 80.05M | 180.06M | 243.94M |
| Other Long-Term Liabilities | 4.47M | 4.35M | 4.12M | 3.89M | ||
| Total Liabilities | 79.16M | 52.56M | 120.99M | 249.24M | 346.64M | 339.87M |
| Common Stock | 2.00K | 2.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Additional Paid-In Capital | 1.05B | 810.84M | 691.10M | 675.90M | 637.12M | 623.34M |
| Retained Earnings | -750.86M | -711.95M | -691.58M | -723.45M | -722.88M | -623.56M |
| Comprehensive Income & Other | -196.00K | 111.00K | 27.00K | 95.00K | 10.00K | -242.00K |
| Shareholders' Equity | 302.07M | 99.01M | -456.00K | -47.45M | -85.75M | -459.00K |
| Total Liabilities & Equity | 381.23M | 151.57M | 120.53M | 201.79M | 260.89M | 339.41M |
| Total Debt | 5.70M | 4.24M | 9.38M | 13.97M | 18.06M | 21.67M |
| Net Cash (Debt) | 324.58M | 132.81M | 91.24M | 160.53M | 175.59M | 283.55M |
| Net Cash Per Share | 1.77 | 0.96 | 1.08 | 2.18 | 2.67 | 4.42 |
| Filing Date Shares Outstanding | 217.90M | 170.19M | 80.10M | 67.72M | 66.23M | 65.39M |
| Total Common Shares Outstanding | 217.90M | 170.19M | 80.10M | 67.31M | 66.23M | 65.39M |
| Working Capital | 333.29M | 97.31M | 21.53M | 27.02M | 84.49M | 232.43M |
| Book Value Per Share | 1.39 | 0.58 | -0.01 | -0.70 | -1.29 | -0.01 |
| Tangible Book Value | 300.75M | 97.62M | -1.99M | -49.12M | -87.58M | -2.43M |
| Tangible Book Value Per Share | 1.38 | 0.57 | -0.02 | -0.73 | -1.32 | -0.04 |
| Machinery | 16.62M | 16.69M | 16.30M | 17.00M | 17.75M | |
| Construction In Progress | 368.00K | 705.00K | 308.00K | |||
| Leasehold Improvements | 1.60M | 2.00M | 1.98M | 1.74M | 1.74M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -79.65M | -17.37M | 31.87M | -569.00K | -99.32M | -115.87M |
| Depreciation & Amortization | 942.00K | 1.38M | 1.77M | 2.17M | 2.44M | 2.71M |
| Asset Writedown & Restructuring Costs | 402.00K | 402.00K | 106.00K | 254.00K | ||
| Loss (Gain) From Sale of Investments | -3.51M | -2.21M | -5.31M | -7.42M | -52.00K | 272.00K |
| Stock-Based Compensation | 10.15M | 6.30M | 7.67M | 8.56M | 13.12M | 13.17M |
| Other Operating Activities | 4.79M | 4.48M | 4.08M | 3.73M | 3.41M | 3.13M |
| Change in Accounts Receivable | -35.62M | 1.09M | 329.00K | 32.55M | -35.20M | 8.00K |
| Change in Accounts Payable | 1.71M | 221.00K | -297.00K | -1.43M | 68.00K | -139.00K |
| Change in Unearned Revenue | 22.40M | -65.60M | -118.25M | -89.01M | 16.57M | -33.95M |
| Change in Other Net Operating Assets | -4.01M | -4.29M | -8.20M | -4.63M | -12.09M | 11.64M |
| Operating Cash Flow | -82.41M | -75.59M | -86.23M | -56.03M | -110.79M | -119.03M |
| Capital Expenditures | -74.00K | -220.00K | -310.00K | -840.00K | -1.74M | -1.61M |
| Investment in Securities | -200.73M | -59.52M | 100.01M | -149.83M | 100.00M | 24.10M |
| Investing Cash Flow | -200.80M | -59.74M | 99.70M | -150.67M | 98.26M | 22.49M |
| Issuance of Common Stock | 246.04M | 110.45M | 7.52M | 561.00K | 648.00K | 110.21M |
| Other Financing Activities | 5.86M | 29.67M | ||||
| Financing Cash Flow | 251.89M | 110.45M | 7.52M | 30.23M | 648.00K | 110.21M |
| Net Cash Flow | -31.32M | -24.89M | 20.99M | -176.48M | -11.88M | 13.67M |
| Free Cash Flow | -82.48M | -75.81M | -86.54M | -56.88M | -112.53M | -120.64M |
| Free Cash Flow Margin | -450.65% | -99.48% | -62.66% | -56.19% | -211.67% | -323.33% |
| Free Cash Flow Per Share | -0.45 | -0.55 | -1.02 | -0.77 | -1.71 | -1.88 |
| Levered Free Cash Flow | -75.21M | -43.21M | -44.20M | 43.66M | -8.92M | -46.11M |
| Unlevered Free Cash Flow | -75.21M | -43.21M | -44.20M | 43.66M | -8.92M | -46.11M |
| Change in Working Capital | -15.53M | -68.58M | -126.42M | -62.51M | -30.65M | -22.44M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 480.47M | 721.79M | 80.61M | 103.83M | 105.73M | 282.53M |
| Enterprise Value | 155.89M | 583.76M | -26.38M | -75.22M | -69.54M | 68.77M |
| Last Close Price | 2.34 | 4.26 | 1.03 | 1.55 | 1.60 | 4.33 |
| PE Ratio | 2.53 | |||||
| Forward PE | 3.03 | 47.98 | 16.30 | |||
| PS Ratio | 27.86 | 9.47 | 0.58 | 1.03 | 1.99 | 7.57 |
| PB Ratio | 1.69 | 7.29 | -176.77 | -2.19 | -1.23 | -615.53 |
| P/TBV Ratio | 1.70 | 7.39 | ||||
| EV/Sales Ratio | 10.12 | 7.66 | 1.84 | |||
| Debt / Equity Ratio | 0.02 | 0.04 | -20.58 | -0.29 | -0.21 | -47.22 |
| Debt / EBITDA Ratio | 0.29 | |||||
| Net Debt / Equity Ratio | -1.07 | -1.34 | 200.08 | 3.38 | 2.05 | 617.76 |
| Net Debt / EBITDA Ratio | 3.77 | 7.30 | -3.41 | 37.26 | 1.92 | 2.50 |
| Net Debt / FCF Ratio | 3.94 | 1.75 | 1.05 | 2.82 | 1.56 | 2.35 |
| Asset Turnover | 0.07 | 0.56 | 0.86 | 0.44 | 0.18 | 0.11 |
| Quick Ratio | 9.26 | 2.98 | 1.21 | 1.14 | 1.50 | 3.93 |
| Current Ratio | 9.36 | 3.09 | 1.25 | 1.17 | 1.55 | 3.98 |
| Return on Equity (ROE) | -37.75% | -35.25% | ||||
| Return on Assets (ROA) | -19.58% | -8.99% | 9.69% | -1.75% | -19.54% | -20.78% |
| Return on Invested Capital (ROIC) | 61.56% | 1.44% | -50.75% | -42.04% | ||
| Return on Capital Employed (ROCE) | -25.50% | -18.60% | 71.90% | -14.10% | -86.70% | -44.40% |
| Earnings Yield | -20.63% | -2.41% | 39.54% | -0.55% | -93.93% | -41.01% |
| FCF Yield | -16.18% | -10.50% | -107.36% | -54.78% | -106.42% | -42.70% |
| Buyback Yield / Dilution | -88.30% | -62.77% | -14.82% | -12.27% | -2.48% | -39.01% |